Literature DB >> 6949614

The contribution of blast cell properties to outcome variation in acute myeloblastic leukemia (AML).

E A McCulloch, J E Curtis, H A Messner, J S Senn, T P Germanson.   

Abstract

The blast cell population in AML includes progenitors capable of colony formation in culture. Certain properties of these progenitors have been determined, including their capacity for self-renewal and their sensitivities to the chemotherapeutic drugs cytosine arabinoside (Ara-C) and adriamycin (Adria). Wide patient to patient variation was found in these properties, although they were stable during the course of the disease in each patient. We tested the properties, together with clinical risk factors, as attributes contributing to the variation in remission induction and survival. As univariate parameters, self-renewal and Ara-C sensitivity contributed to remission induction, but only self-renewal was related to survival. In multivariate analysis, self-renewal, age and percentage blasts in the marrow contributed to outcome variation; drug sensitivities were not significant. We conclude that self-renewal, a biological property of malignant AML clones, although measured in culture, plays a significant role in determining response to treatment and survival in AML.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6949614

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Disconnection of genes coding for self-renewal and differentiation: a possible mechanism of diversity in acute myeloid leukemias.

Authors:  H von Melchner; K Höffken
Journal:  Blut       Date:  1985-05

Review 2.  Properties and identification of cancer stem cells: a changing insight into intractable cancer.

Authors:  Norikatsu Miyoshi; Hideshi Ishii; Mitsugu Sekimoto; Naotsugu Haraguchi; Yuichiro Doki; Masaki Mori
Journal:  Surg Today       Date:  2010-06-26       Impact factor: 2.549

Review 3.  Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions.

Authors:  L M Hollingshead; K L Goa
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

4.  Inhibition of the self-renewal capacity of blast progenitors from acute myeloblastic leukemia patients by site-selective 8-chloroadenosine 3',5'-cyclic monophosphate.

Authors:  A Pinto; D Aldinucci; V Gattei; V Zagonel; G Tortora; A Budillon; Y S Cho-Chung
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

5.  Adriamycin and cytosine arabinoside contribute equally to prediction of response in acute myelocytic leukemia with improved confidence level.

Authors:  M G Lihou; P J Smith
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Replating efficiency of metastatic melanoma cells from lymph node and subcutaneous sites does not predict patient survival.

Authors:  F L Meyskens; S P Thomson; J Buckmeier
Journal:  Clin Exp Metastasis       Date:  1989 Nov-Dec       Impact factor: 5.150

7.  Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival.

Authors:  Yanping Guo; Kathleen Köck; Christoph A Ritter; Zhe-Sheng Chen; Markus Grube; Gabriele Jedlitschky; Thomas Illmer; Mary Ayres; James F Beck; Werner Siegmund; Gerhard Ehninger; Varsha Gandhi; Heyo K Kroemer; Gary D Kruh; Markus Schaich
Journal:  Clin Cancer Res       Date:  2009-02-24       Impact factor: 12.531

8.  Cytogenetic investigations on children with acute non-lymphocytic leukemia.

Authors:  E Oláh; E Balogh; J Szollár; E Szakmáry; I Kovács; D Schuler; L Karmazsin
Journal:  Blut       Date:  1988-06

9.  Differentiation-linked secretion of urokinase and tissue plasminogen activator by normal human hemopoietic cells.

Authors:  E L Wilson; G E Francis
Journal:  J Exp Med       Date:  1987-06-01       Impact factor: 14.307

10.  In vitro sensitivity of clonogenic cells in resisting and relapsing patients with acute myelogenous leukaemia.

Authors:  J P Marie; R Zittoun; D Thevenin
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.